This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Buist, M. R. Articles by Roos, J. C. Search for Related Content PubMed PubMed Citation Articles by Buist, M. R. Articles by Roos, J. C.

Kinetics and Tissue Distribution of the Radiolabeled Chimeric Monoclonal Antibody MOv18 IgG and F(ab')₂ Fragments in Ovarian Carcinoma Patients¹

Departments of Obstetrics and Gynecology [M. R. B., P. K., C. J. M. M., C. W. B.], Nuclear Medicine [W. d. H., J. C. R.], Medical Oncology [J. B. V.], and Pathology [J. P. A. B.], Free University Hospital, De Boelelaan 1117, 1081 HV Amsterdam, and Department of Gynecology [T. J. M. H.], Netherlands Cancer Institute, Plesmalaan 121, 1066 CX, Amsterdam, The Netherlands

Twenty-four patients suspected of having ovarian carcinoma received i.v. injection with a combination of radiolabeled intact IgG (1 mg) and F(ab')₂ fragments (1 mg) of the chimeric monoclonal antibody MOv18, each form labeled with 1.85 MBq ¹³¹I or ¹²⁵I. Laparotomy was performed either 2 or 6 days after injection, and the uptake of radioactivity was determined in a total of 329 biopsies of normal and malignant tissues.

The mean elimination half life in plasma of cMOv18 IgG and F(ab')₂ was 70 ± 8 (SD) and 20 ± 5 h, respectively. The mean uptake of IgG in tumor biopsies was 3.6-fold higher two days after injection and 6.9-fold higher than the uptake of F(ab')₂ 6 days after injection. Uptake in normal tissues was 3.3 and 5.5 times higher for IgG at 2 and 6 days, respectively. Two days after injection, the mean ratio of the uptake in tumor:normal tissue/patient was 3.8 ± 1.5 and 4.0 ± 1.8 for radiolabeled cMOv18 IgG and F(ab')₂, respectively. Six days after injection, this was 6.7 ± 4.7 for Ig G and 5.7 ± 4.1 for F(ab')₂.

cMOv18 IgG has a longer circulation time in blood, a higher uptake in tumor and normal tissues, and a longer retention time compared to the F(ab')₂ fragments. However, the tumor:normal tissue ratios are similar. The results do not warrant a definite conclusion as to which antibody form is most suitable for therapeutic application of antibodies but provide a more firm basis for rational design of therapeutic targeting studies using immunoconjugates.

¹ This study was supported by Clinical Research Grant NWO 900-716-020 of the Netherlands Organization for Scientific Research and by Grant 92-05 from the Biocare Foundation.

² To whom requests for reprints should be addressed, at Department of Obstetrics and Gynecology, Free University Hospital, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.

Received 4/ 5/93. Accepted 9/ 8/93.

This article has been cited by other articles:

				H. N.J.M. Greuter, R. Boellaard, A. van Lingen, E. J.F. Franssen, and A. A. Lammertsma Measurement of 18F-FDG Concentrations in Blood Samples: Comparison of Direct Calibration and Standard Solution Methods J. Nucl. Med. Technol., December 1, 2003; 31(4): 206 - 209. [Abstract] [Full Text] [PDF]

				G. W. Visser, R. P. Klok, J. W. K. Gebbinck, T. ter Linden, G. A. van Dongen, and C. F. Molthoff Optimal Quality 131I-Monoclonal Antibodies on High-Dose Labeling in a Large Reaction Volume and Temporarily Coating the Antibody with IODO-GEN J. Nucl. Med., March 1, 2001; 42(3): 509 - 519. [Abstract] [Full Text]